Search research articles
Contact Us
Filters
Showing results (101-110 of 482) with videos related to
Page
of 49
Sort By:
Comprehensive Psychiatry
|
May 7, 2013
Craving Typology Questionnaire (CTQ): a scale for alcohol craving in normal controls and alcoholics
Giovanni Martinotti, Marco Di Nicola, Daniela Tedeschi, et al.
Pharmaceuticals (Basel, Switzerland)
|
May 28, 2022
A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases
Stefania Chiappini, Rachel Vickers-Smith, Amira Guirguis, et al.
Frontiers in Psychiatry
|
December 19, 2014
Allostasis as a conceptual framework linking bipolar disorder and addiction
Mauro Pettorruso, Luisa De Risio, Marco Di Nicola, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
March 3, 2023
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
Giacomo d'Andrea, Mauro Pettorruso, Giorgio Di Lorenzo, et al.
Brain Sciences
|
September 27, 2025
Clinical Management of Synthetic-Cannabinoid-Induced Psychosis: A Systematic Review of Treatment Strategies and Outcomes
Alessio Mosca, Stefania Chiappini, Andrea Miuli, et al.
Schizophrenia Research. Cognition
|
September 11, 2025
Anomalous self-experience in schizophrenia spectrum disorders: Phenomenological and psychopathological correlates
Alessio Mosca, Stefania Chiappini, Arianna Pasino, et al.
Human Psychopharmacology
|
July 29, 2015
Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products
Rita Santacroce, Ornella Corazza, Giovanni Martinotti, et al.
CNS Spectrums
|
June 26, 2020
Substance-related exogenous psychosis: a postmodern syndrome
Giovanni Martinotti, Luisa De Risio, Chiara Vannini, et al.
Addiction Biology
|
May 19, 2010
Ecstasy (MDMA)-addicted subjects show increased serum levels of brain-derived neurotrophic factor, independently from a rise of drug-induced psychotic symptoms
Francesco Angelucci, Valerio Ricci, Giovanni Martinotti, et al.
Human Psychopharmacology
|
November 19, 2016
Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study
Pedro Damian Gargoloff, Ricardo Corral, Luis Herbst, et al.
Page
of 49
Search research articles
Search
Showing results (101-110 of 482) with videos related to
Sort By:
Page
of 49
Comprehensive Psychiatry
|
May 7, 2013
Craving Typology Questionnaire (CTQ): a scale for alcohol craving in normal controls and alcoholics
Giovanni Martinotti, Marco Di Nicola, Daniela Tedeschi, et al.
Pharmaceuticals (Basel, Switzerland)
|
May 28, 2022
A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases
Stefania Chiappini, Rachel Vickers-Smith, Amira Guirguis, et al.
Frontiers in Psychiatry
|
December 19, 2014
Allostasis as a conceptual framework linking bipolar disorder and addiction
Mauro Pettorruso, Luisa De Risio, Marco Di Nicola, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
March 3, 2023
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
Giacomo d'Andrea, Mauro Pettorruso, Giorgio Di Lorenzo, et al.
Brain Sciences
|
September 27, 2025
Clinical Management of Synthetic-Cannabinoid-Induced Psychosis: A Systematic Review of Treatment Strategies and Outcomes
Alessio Mosca, Stefania Chiappini, Andrea Miuli, et al.
Schizophrenia Research. Cognition
|
September 11, 2025
Anomalous self-experience in schizophrenia spectrum disorders: Phenomenological and psychopathological correlates
Alessio Mosca, Stefania Chiappini, Arianna Pasino, et al.
Human Psychopharmacology
|
July 29, 2015
Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products
Rita Santacroce, Ornella Corazza, Giovanni Martinotti, et al.
CNS Spectrums
|
June 26, 2020
Substance-related exogenous psychosis: a postmodern syndrome
Giovanni Martinotti, Luisa De Risio, Chiara Vannini, et al.
Addiction Biology
|
May 19, 2010
Ecstasy (MDMA)-addicted subjects show increased serum levels of brain-derived neurotrophic factor, independently from a rise of drug-induced psychotic symptoms
Francesco Angelucci, Valerio Ricci, Giovanni Martinotti, et al.
Human Psychopharmacology
|
November 19, 2016
Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study
Pedro Damian Gargoloff, Ricardo Corral, Luis Herbst, et al.
Page
of 49